Construction of New Research, Development and Manufacturing Facilities for Drugs Using Innovative Modalities/Technologies Including Antibodies and Cell Therapies Announced by Astellas 글 내용 전체보기
Sandoz Decides Not To Pursue US Biosimilar Rituximab; Will Focus On Robust Biosimilar Portfolio For Unmet Access And Sustainability Needs 글 내용 전체보기